Certificate of Analysis
Independent laboratory testing confirms purity and composition of this research compound.
ENDO PASSED
Stack Rationale
The CJC/Ipamorelin Stack pairs two mechanistically complementary growth hormone secretagogues: CJC-1295 No DAC, a modified GHRH analogue that drives pituitary somatotroph stimulation, and Ipamorelin, a highly selective ghrelin receptor (GHS-R1a) agonist that mimics the endogenous pulsatile GH signal. When co-administered, these two pathways converge on the pituitary somatotroph from distinct receptor classes, producing synergistic GH pulse amplification that exceeds what either compound achieves alone — a phenomenon well-characterised in preclinical and early clinical literature on combined GHRH/GHS therapy.
What’s Included
| Compound | Vial dose | Qty | Mechanism |
| CJC-1295 No DAC (Modified GRF 1-29) | 5 mg | 1 vial | GHRH receptor agonist — somatotroph stimulation |
| Ipamorelin | 5 mg | 1 vial | GHS-R1a agonist — ghrelin-pathway GH pulse trigger |
| Form | Lyophilized powder (all vials) |
| Purity | ≥99% (HPLC verified, per vial) |
| Mass confirmation | ESI-MS confirmed (per vial) |
| Heavy metals | <10 ppm (ICP-MS) |
| Endotoxin | <1.0 EU/mg (LAL) |
| Residual moisture | <5.0% (Karl Fischer) |
| Storage — lyophilized | −20°C, protected from light |
| Lyophilized stability | 24 months from manufacture |
| Reconstitution | Bacteriostatic water for injection (per compound) |
| Storage — reconstituted | 4°C, use within 28 days |
| Packaging | Sterile glass vials · rubber stoppers · aluminium crimp caps |
Mechanism of Synergy
Endogenous GH release is regulated by two opposing hypothalamic inputs: GHRH (stimulatory) and somatostatin (inhibitory). The ghrelin receptor pathway (GHS-R1a) operates orthogonally — it not only directly stimulates somatotrophs but also suppresses somatostatin release, disinhibiting the GHRH effect. CJC-1295 No DAC drives the GHRH side of this axis; Ipamorelin drives the ghrelin-receptor side. The result is dual amplification: more stimulation + less inhibition = substantially greater GH pulse amplitude than either compound produces in isolation.
| Pathway | CJC-1295 No DAC | Ipamorelin |
| Receptor target | GHRHR (pituitary) | GHS-R1a (pituitary + hypothalamus) |
| Somatostatin suppression | Indirect (weak) | Direct (strong) |
| GH pulse amplitude | ↑ Moderate | ↑ Moderate |
| Combined effect | ↑↑ Synergistic (additive to supra-additive) | |
| IGF-1 downstream | ↑ proportional to GH elevation | |
| Cortisol / prolactin | Minimal perturbation (Ipamorelin’s selectivity advantage) | |
Research Notes
Published rodent and primate studies consistently show that combined GHRH + GHS administration produces GH area-under-curve values 2–3× those of matched-dose monotherapy. The “No DAC” formulation of CJC-1295 (Modified GRF 1-29) is preferred for pulsatile research designs because its shorter half-life (~30 minutes) preserves physiological GH pulsatility rather than producing sustained elevation. Ipamorelin’s well-established selectivity for GHS-R1a over cortisol and prolactin axes makes it the preferred ghrelin mimetic when clean, GH-selective readouts are required.
Frequently Asked Questions
- Why No DAC and not CJC-1295 DAC in this stack?
- CJC-1295 DAC has a multi-day half-life and produces continuous, sustained GH elevation rather than pulsatile release. The No DAC (Modified GRF 1-29) version mirrors the short burst of endogenous GHRH, which pairs more naturally with Ipamorelin’s pulsatile GHS-R1a trigger. Researchers studying authentic pulsatile GH physiology consistently prefer the shorter-acting GHRH analogue in combination protocols.
- What are the typical research dosing intervals for this combination?
- In rodent models, administration 2–3× daily (matching natural GH pulse windows — early morning and pre-sleep equivalents) is common. In non-human primate models, a twice-daily protocol is standard. The interval design must account for receptor recovery time between pulses to avoid desensitisation.
- Are the two vials reconstituted separately?
- Yes. Each compound should be reconstituted separately in bacteriostatic water. In vitro protocols requiring combined exposure should prepare each solution independently before combining at the assay concentration step.
What compounds are in the The CJC/Ipamorelin Stack?
The The CJC/Ipamorelin Stack includes: CJC-1295 No DAC / Modified GRF 1-29 (5 mg × 1) and Ipamorelin (5 mg × 1). This stack combines two mechanistically complementary growth hormone secretagogues: CJC-1295 (GHRH analogue targeting pituitary somatotroph GHRHR) and Ipamorelin (selective GHS-R1a agonist mimicking endogenous pulsatile GH signal). When co-administered, these converge on the somatotroph from distinct receptor classes, producing synergistic GH pulse amplification well-characterised in preclinical and early clinical literature.
Are the The CJC/Ipamorelin Stack vials pre-mixed or individual?
Yes — each compound ships as a separate, individually labelled lyophilized vial. They are not pre-mixed. Each vial is labelled with compound name, dose, batch number, and storage instructions to ensure clear identification throughout the research workflow.
What purity are the compounds in the The CJC/Ipamorelin Stack?
All compounds are ≥99% by HPLC, with ESI-MS mass confirmation and endotoxin testing to USP <85> standards. Full Certificate of Analysis documentation is available on the COA page and traceable by batch number for each compound.
Is this for human consumption?
No. The The CJC/Ipamorelin Stack from BIOHACKER is sold strictly for in vitro research and laboratory use. It is not intended for human or veterinary use and is not a dietary supplement or pharmaceutical product.
Ready to order? Add to Cart — $90
Research Use Only. This product is intended for in-vitro laboratory research purposes only. Not for human consumption, clinical use, veterinary use, or food/drug manufacturing. Not evaluated or approved by the FDA or any regulatory authority. Handle with appropriate laboratory precautions. Keep out of reach of children.
Reviews
There are no reviews yet.